Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
It was a somewhat ordinary day for David Pyott, the CEO of Allergan, back in April 2014. That is until his eyes glanced over at the TV screen in his office, where he learned that billionaire hedge fund manager and activist investor Bill Ackman was about to back the takeover of his company by way of a hostile takeover.
The acquirer was none other than the infamous and controversial pharmaceutical company, Valeant Pharmaceuticals. Valeant was a Wall Street darling and one of Canada’s largest companies. So why and how did this transaction lead to Valeant’s downfall only a year later?
Stream the new episode below, listen and subscribe on Apple Podcasts or find it on Spotify.
